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Abstract 
Background: An accurate assessment of septic patients at risk for poor clinical outcomes is challenging for clinicians 
in the emergency department (ED).
Objectives: We aimed to evaluate the prognostic value of procalcitonin (PCT) in septic patients in the ED for predict‑
ing death.
Results: In a retrospective study, 188 septic patients (median age 63 [IQR 51–80]) of two French university hospi‑
tals were included. Patients who deceased within 30 days (20 %, n = 37) presented higher PCT value at admission 
(median 34.0 µg/L [5.0–71.9]) in comparison with the survivals (median 6.4 µg/L [4.1–13.1], p = 0.0005). ROC curve 
analysis indicated a moderate AUC of 0.686 [95 % CI 0.613–0.752] and an optimal PCT threshold value at 32.5 [95 % 
CI 21.8–43.3] µg/L that was associated with a 51 % [34–67] sensitivity, a 96 % [90–98] specificity, a 73 % [52–88] 
positive predictive value, and a 89 % [83–93] negative predictive value for death. Only 26 patients (14 %) had PCT 
values above this threshold (19 in the deceased group vs 7 in survival group, p < 0.0001). By multivariate analysis, 
only three variables remained significantly predictive of the death: personal history of cardiovascular disease (OR 3.1 
[1.0–9.4], p = 0.046), the presence of severe sepsis/septic shock in the ER (OR 4.4 [1.3–12.3], p = 0.013), and a PCT level 
>32.5 µg/L (OR 36.0 [10.0–128.4], p < 0.0001). Similar results were obtained when considering the combined outcome 
death and/or admission in ICU.
Conclusion: Elevated value of PCT at admission has moderate accuracy to identify poor outcome in ED septic 
patients in daily practice.
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Background
Sepsis is a life-threatening condition that arises when the 
host’s response to an infection injures its own tissues and 
organs [1]. The accurate identification of sepsis is one 
of the main challenges in emergency medicine. Despite 
advances in antibiotic therapy and modern life support, 
fatality rate of patients with sepsis has remained high 
worldwide (>30 %) [1, 2].
Early identification of patients at high risk of dying 
from sepsis may help initiate rapid and appropriate 
therapeutic interventions. However, signs of organ dys-
function may not be obvious for the physician’s at the 
time of presentation [3]. Thus, an accurate assessment of 
patients at risk for poor clinical outcomes is challenging 
for clinicians in the emergency department (ED).
Procalcitonin (PCT), the pro-hormone of calcitonin, 
is synthesized by thyroid cells. During sepsis, many tis-
sues and immune cells become able to secrete PCT. The 
enhanced specificity of PCT along with the publication of 
numerous clinical and interventional studies has contrib-
uted to the growing interest and implementation of PCT 
in the ED as a biomarker of the systemic host response 
to bacterial invasion [3, 4]. Several studies have demon-
strated that PCT may confer prognostic information in 
PAC [5] and in sepsis [6], and some have suggested the 
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same in an ED. Recently, PCT-based sepsis diagnosis 
was demonstrated to be more reliable and discriminat-
ing than clinical sepsis diagnosis [7]. Furthermore, lac-
tate and PCT might be complementary biomarkers for 
the risk stratification of ED patients evaluation [3]. Thus, 
PCT might be a good candidate to accurately identify ED 
septic patients with poor outcome.
Therefore, we aimed to evaluate the prognostic value of 
PCT in septic patients in the ED.
Patients and methods
It was a retrospective study, which took place in the EDs 
of two university hospitals (Tenon hospital in Paris and 
Rouen), from July 2011 to December 2011. Both were 
urban adult ED and teaching hospitals with, respec-
tively, 45,000 and 82,000 annual new patient attendances. 
Because of the observational design of the study, the ethi-
cal committee (CPP Ile-de-France Paris VI, Paris, France) 
authorized a waiver of informed consent. In these two 
hospitals, PCT is widely used by physicians’ in charge, for 
patients with suspected or confirmed infections, espe-
cially in suspicion of lower respiratory tract infections. 
However, no real guideline is associated with the result 
of PCT.
Studied population
Patients ≥18  years old were included if they presented 
with a confirmed diagnosis of infection, and had a PCT 
measurement blood sampled routinely performed in the 
ED with a level ≥2 µg/L. This PCT threshold was chosen 
upon previous studies observations, where ED patients 
with PCT ≥2 µg/L were suggested as having a sepsis and 
high risk of development of organ dysfunction [4, 8]. For 
each patient, ED electronic file and recorded admission 
data (including initial vital variables, routine biological 
data, and admitting diagnosis in ED) were collected, as 
well as outcome (discharge, admission to a medical ward 
or ICU, in-hospital mortality) and final diagnosis, i.e., 
each patient had a confirmation of sepsis suspected in 
the ED (based on all medical charts and available micro-
biological data). The presence of systemic inflamma-
tory response syndrome (SIRS), sepsis, or severe sepsis/
septic shock criteria [9] was also recorded, either at ED 
admission or during follow-up. For this study, hyperlac-
tatemia (>2 mmol/L) was used as a severe sepsis criterion 
(although not specific) [10]. However, patients with other 
causes of high lactate levels were not excluded.
Patients were further categorized according to two dif-
ferent outcomes: death at day 30, or a combined outcome 
of death and/or admission to ICU during the follow-up 
of day 30.
PCT measurement
In Tenon hospital, PCT concentrations were analyzed 
using a sandwich immunoassay based on time-resolved 
amplified cryptate emission (TRACE) measurement 
(Kryptor analyzer; B.R.A.H.M.S. Thermo Fischer, Ger-
many). In our laboratory, coefficients of variation (CV) 
for PCT were found to be <10 % at 0.28 and 10.8 µg/L. 
In Rouen hospital, procalcitonin concentrations were 
analyzed using an electrochemiluminescent immunoas-
say (ELECSYS BRAHMS procalcitonin, Hennigsdorf, 
Germany), performed on a Cobas e601 analyzer (Roche 
Diagnostics, Meylan, France). In our laboratories, coef-
ficients of variation for procalcitonin were <4  % at 2 
concentrations during the study period. Both methods 
are correlated [11]. In our laboratories, correlation coef-
ficient was R2  =  0.964 (slope: 1.04, intercept: −0.73), 
and we observed 96.4  % of concordance between the 
two methods (data not shown). Median bias observed 
between the two methods was 11 %, which is acceptable 
[12]. The upper reference limit (URL) announced by the 
manufacturer was 0.046 µg/L.
Statistical analysis
Results were expressed as medians [interquartile range, 
IQR] for continuous variables and numbers (percent-
age) for discrete variables. Data were compared using 
the Kruskal–Wallis test for continuous variables, and the 
Chi-square for differences in frequencies.
Receiver operating characteristic (ROC) analysis was 
performed in order to determine the best thresholds 
for PCT (or the combination of PCT +  lactate after log 
transformation) which would be predictive of the out-
come. Because of the possible impact of sample size on 
threshold value, a bootstrap analysis (1000 random sam-
ples with replacement) was performed to obtain a cal-
culation of the optimal threshold of PCT and its 95  % 
confidence interval [13]. We assessed the sensitivity and 
specificity, positive (PPV) and negative predictive value 
(NPV) (all with their 95 % confidence intervals [95 % CI], 
calculated with the Wilson’s score with correction of con-
tinuity) for thresholds.
As the ROC curve is recognized to be potentially insen-
sitive, the net reclassification index (NRI) method was 
used, as described [13]. For tests with binary outcomes, 
NRI is the same as the gain in certainty of the first test 
minus the gain in certainty of the second test, or alterna-
tively stated, the differences in the sum of the sensitivity 
and specificity:
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Since NRI is a powerful statistical tool, significant 
results might only have a poor clinical impact. In order to 
illustrate the improvement given by lactate in association 
with PCT, we provide a reclassification table that enables 
us to quantify the benefit of the association in terms of 
number of patients correctly reclassified. Furthermore, 
the reclassification table offers a practical representation 
of both the relationship between false positive and false 
negative, and the magnitude of the gain of predictability 
in quantitative terms (number of patients).
We further evaluated PCT and lactate combination 
using the best linear combination (BLC) method [14]. 
Briefly, this method relies on the creation of a formula in 
which PCT and lactate are moderated by their coefficient 
of covariance in the studied population. The obtained 
combination gives a score for each patient that can be 
studied as a biomarker by itself and submitted to ROC 
analysis and logistic regression.
A forward logistic regression was performed to assess 
variables associated with outcome. For this analysis, 
PCT levels were evaluated as categorical variables based 
on the optimum cutoff point previously determined by 
ROC curve. We adopted a conservative approach and 
only included significant preoperative variables in the 
univariate analysis (p value of entry <0.10). The discrimi-
nate power of the logistic regression was evaluated by the 
c-statistic (concordance index) and the goodness of fit of 
the model by the Hosmer–Lemeshow test.
The results were analyzed using Med Calc 3.4.2.0 for 
Windows (MedCalc Software, Mariakerke, Belgium). All 
tests were two-tailed. A p value <0.05 was considered to 
be statistically significant.
Results
Main characteristics of the studied population (n = 188) 
are presented in Table  1. As expected, main sources of 
sepsis were pulmonary and urinary infections. Forty-
three percent of patients had a severe sepsis/septic shock, 
and 28 % were transferred in ICU. Briefly, patients who 
deceased within 30 days (20 %; n = 37) were older, pre-
sented an initial higher cardiac rate and respiratory rate, 
had more comorbidity, had more frequently severe sepsis 
or septic shock, and presented higher lactate levels than 
survivals. Of note, there was no difference in age values 
between recruitment sites (p =  0.337). Ninety-one per-
cent of patients were admitted to the hospital.
Patients with severe sepsis/septic shock had higher car-
diac rate (110 [94–125] vs. 96 [84–110], p = 0.001) and 
respiratory rate (30 [24–38] vs. 20 [18–26], p =  0.003), 
higher lactate (2.4 [1.7–3.6] vs. 1.9 [1.5–2.8] mmol/L, 
p =  0.053), and lower diastolic blood pressure (62 [51–
75] vs. 76 [64–84], p < 0.0001), lower systolic blood pres-
sure (99 [88–119] vs. 129 [107–148], p  <  0.0001), and 
higher SpO2 (96 [94–98] vs. 94 [91–98]  %, p  =  0.041), 
than those without severe sepsis/septic shock. Fur-
thermore, patients admitted to ICU were younger (60 
[49–81] vs. 69 [52–83] years, p = 0.011), had lower dias-
tolic blood pressure (62 [50–76] vs. 73 [61–81] mm Hg, 
p =  0.005), lower systolic blood pressure (100 [90–126] 
vs. 120 [100–139] mm Hg, p = 0.005), higher respiratory 
rate (32 [27–39] vs. 24 [20–32], p = 0.010), higher lactate 
(2.5 [2.0–3.4] vs. 2.1 [1.5–2.9]  mmol/L, p =  0.039), and 
presented more frequently severe sepsis/septic shock (68 
vs. 38 %, p = 0.001), than patients not admitted to ICU.
The median PCT value was higher in the deceased 
group (median [interquartile range, IQR]) (34.0  µg/L 
[5.0–71.9]) in comparison with the survivals (6.4 [4.1–
13.1]  µg/L, p  =  0.0005) (Fig.  1). However, PCT values 
were not significantly higher in patients admitted to ICU 
in comparison with the others (9.6 [4.1–18.2] vs. 6.1 [3.9–
14.1] µg/L, p = 0.145); same observation was done when 
comparing PCT values between patients with severe sep-
sis/septic shock versus others (8.6 [4.9–23.7] vs. 6.2 [3.6–
12.3] µg/L, p = 0.064). Of note, there was no difference in 
PCT values between recruitment sites (p = 0.674).
ROC analysis
The ROC curve analysis indicated a moderate accuracy, 
with an AUC at 0.686 [95 % CI 0.613–0.752] (p = 0.002) 
for PCT to predict 30-day mortality (Fig.  2a). Defined 
by the ROC curve, the optimal threshold value was 32.5 
[95 % CI 21.8–43.3] µg/L and was associated with a 51 % 
[34–67] sensitivity, a 96 % [90–98] specificity, a 73 % [52–
88] PPV, and a 89 % [83–93] NPV. Only 26 patients (14 %) 
had PCT values above this threshold. The proportion of 
patients with PCT > 32.5 µg/L in the deceased group was 
significantly higher (51  %, n  =  19) than in the survival 
group (5 %, n = 7) (p < 0.0001). However, the proportion 
of patients with PCT  >  32.5  µg/L in the severe sepsis/
septic shock (19 %, n = 16) was not significantly different 
from the proportion of patients with PCT > 32.5 µg/L in 
patients without severe sepsis/septic shock (10 %, n = 12) 
(p = 0.123).
The ROC curve analysis indicated a moderate accu-
racy for PCT to predict death and/or admission in ICU, 
with an AUC at 0.644 [0.571–0.712] (p = 0.007), with an 
optimal threshold value at 9.9 µg/L (Fig. 2b). This thresh-
old was associated with a 54 % [42–65] sensitivity, a 73 % 
[63–90] specificity, a 70 % [61–78] PPV, and a 57 % [45–
68] NPV.
When patients were classified according to PCT cate-
gories (arbitrarily defined as PCT < 5 µg/L, PCT between 
5 and 19.9  µg/L, PCT between 20 and 31.9  µg/L, and 
PCT ≥ 32 µg/L), we observed that mortality raised dra-
matically only in patients with PCT ≥ 32 µg/L, while ICU 
transfer was not affected by PCT value (Fig. 3).
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Analysis of subgroup in patients with available lactate 
measurement
When considering patients with available lactate meas-
urement (n  =  103), patients with PCT  >  32.5  µg/L 
presented higher median lactate values (3.3 [1.9–
4.3]  mmol/L), in comparison with patients with lower 
PCT (2.1 [1.5–3.0] mmol/L, p = 0.0347).
When combining PCT and lactate log-transformed 
values, the ROC curve analysis indicated an AUC 
at 0.692 [95  % CI 0.594–0.780] for the prediction of 
30-day mortality. This was significantly higher than 
PCT alone in this subgroup (p =  0.020). However, sen-
sitivity (50 %) and specificity (96 %) were similar to those 
obtained with PCT alone. Alternatively, using the BLC 
method, we obtained the following combination: PCT 
(in µg/L) + 0.025 ×  lactate (in mmol/L). This combina-
tion gives a score for each patient and was tested in ROC 
analysis. Unfortunately, it failed to maximize ROC curve 
(AUC = 0.633 [0.533–0.726] vs. PCT alone, p = 0.061).
Patients with both PCT  >  32.5  µg/L and lactate 
>2.2 mmol/L (i.e., above ROC thresholds) presented the 
worse outcome if considering death at day 30 (p < 0.0001) 
Table 1 Characteristics of the studied population
Results are in mean ± SD, median (25th–75th percentile), or number (percentage)
* Between patients deceased and survival
a Mainly pulmonary and urinary concomitant bacterial infection
b Bacterial infection (ENT, blood stream infection from unknown origin)
c Non-bacterial infection (i.e., parasitic, fungic, or mycobacterium infection)
All patients Deceased at 30 days Survival p*
n 188 37 151
Patients of Rouen [n (%)] 97 (52) 21 (57) 76 (50) 0.605
Patients of Tenon [n (%)] 91 (48) 16 (43) 75 (50) vs Tenon
Age (years) 63 (51–80) 78 (63–83) 64 (46–78) 0.001
Men [n (%)] 101 (54) 22 (59) 79 (52) 0.551
Temperature (°C) 38.1 (37.1–39.0) 38.2 (37.1–39.8) 38.1 (37.0–38.8) 0.321
Systolic blood pressure (mmHg) 113 (96–137) 113 (93–136) 116 (97–137) 0.524
Diastolic blood pressure (mmHg) 70 (57–80) 65 (52–81) 72 (59–80) 0.260
Cardiac rate, in bpm 100 (87–118) 110 (95–129) 99 (85–116) 0.051
Respiratory rate (RR) (n = 74) 26 (20–34) 32 (29–40) 25 (20–32) 0.009
SpO2 in % 95.0 (92.5–98.0) 95.0 (91.0–97.5) 95.0 (93.0–98.0) 0.636
Personal history of:
 Cardiovascular disease [n (%)] 94 (50) 24 (65) 70 (46) 0.052
 Respiratory disease [n (%)] 43 (23) 13 (35) 30 (20) 0.063
 Other (chronic) [n (%)] 51 (27) 5 (14) 46 (30) 0.099
Immunosuppressors, corticoids, or chemotherapy [n (%)] 29 (15) 5 (14) 24 (16) 0.677
Bacterial infection [n (%)] 139 (74) 27 (73) 112 (74) 0.159
 Pulmonary infection [n (%)] 59 (31) 7 (19) 52 (34) 0.085
 Urinary infection [n (%)] 30 (16) 5 (14) 25 (17) 0.914
 Abdominal infection [n (%)] 21 (11) 7 (19) 14 (9) 0.169
 Skin/tissue infection [n (%)] 8 (4) 3 (8) 5 (3) 0.361
 Meningitis [n (%)] 2 (1) 1 (3) 1 (1) 0.828
 Several sitesa 12 (6) 1 (3) 11 (7) 0.526
 Other siteb 7 (4) 3 (8) 4 (3) 0.264
Viral infection [n (%)] 3 (2) 1 (3) 2 (1) 0.835
Other infection [n (%)]c 46 (24) 9 (24) 37 (25) 0.669
Severe sepsis/septic shock [n (%)] 81 (43) 22 (59) 59 (39) 0.040
Median lactate (mmol/L) (n = 103) 2.2 (1.5–3.2) 3.1 (2.2–4.4) 2.1 (1.5–2.8) 0.003
Median white blood cells (G/L) 12.1 (7.9–18.4) 12.1 (9.0–17.4) 12.0 (7.5–18.7) 0.966
Hospital admission [n (%)] 172 (91) 33 (89) 139 (92) 0.818
Admission in ICU [n (%)] 52 (28) 14 (38) 38 (25) 0.181
Length of hospitalization (days) 9 (5–14) 5 (2–10) 10 (6–16) <0.0001
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(Fig.  4). Using these thresholds, a table of contingency 
was built (Table 2), and NRI was calculated. The NRI was 
0.8 % (p = 0.980), indicating that patients were not sig-
nificantly better identified as at risk of death using lactate 
on top of PCT alone.
When considering the prediction of death and/or 
admission in ICU, the combination of PCT and lactate 
indicated an AUC at 0.677 [95 % CI 0.578–0.765], which 
was significantly higher than PCT alone in this subgroup 
(p  =  0.012). However, sensitivity (50  %) and specificity 
(73 %) were similar to those obtained with PCT alone.
Multivariate analysis
Multivariate analysis was performed on the entire 
study group and is presented in Table 3. Three variables 
remained independently and significantly predictive of 
death at day 30: previous history of cardiovascular dis-
ease, the presence of severe sepsis/septic shock, and a 
PCT > 32.5 µg/L, which remained the strongest predictor 
of death. If considering prediction of death and/or admis-
sion to ICU, a PCT value >32.5  µg/L also remained the 
strongest independent and significant predictor, with an 
OR value at 6.4 [2.3–17.9] (p = 0.0004), with the presence 
of severe sepsis/septic shock (OR 4.4 [2.2–8.9]).
If considering prediction of death and/or admission to 
ICU, the PCT  +  lactate score remained the only inde-
pendent and significant predictor of death, with an OR 
value at 6.0 [95 % CI 1.3–28.5] (p = 0.024).
Discussion
We aimed to evaluate in the emergency setting the prog-
nostic value of PCT in septic patients. Our results dem-
onstrated that PCT is a potential tool by itself for early 
identification of ED septic patients with poor outcome 
(death at day 30). However, its prognostic accuracy is not 
useful enough, to be used in daily practice.
A recent meta-analysis indicated that elevated PCT 
concentrations are associated with all-cause mortality 
in septic patients. However, studies are still lacking to 
define the optimal cutoff point, especially in ED patients 
[1]. This previous meta-analysis pointed out the hetero-
geneity of the results observed in the studies. In the spe-
cific field of ED patients, there are few studies that report 
association of PCT level with mortality [15–17]. Authors 
present heterogeneity in methodologies (fully automated 
or semiquantitative assays), in reported cutoffs (from 0.9 
to 10 µg/L), and in testing time (day 0, 1 or 5). In addi-
tion to these data, the study of Freund et al. [3] indicated, 










Fig. 1 PCT values according to 30‑day mortality




























Fig. 2 AUC of PCT to predict 30‑day mortality (a) or to predict death 
and/or admission in ICU (b)
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Brahms), a cutoff at 0.8 µg/L for identification of severe 
outcome in the ED. Thus, relationship between PCT and 
prognosis required further study.
To our knowledge, our study is the first to focus on 
patients with high-PCT values (above 2  µg/L) in emer-
gency septic patients. Our results suggest a moderate 
relation between PCT level and outcome, in the specific 
population of septic patients with high PCT. As expected, 
we find a higher cutoff than previous studies performed 
in ED [3, 15–17], but we also had a better specificity. 
In terms of patients’ recruitment, our results should be 
compared to those of Hur et al. [7] who investigated the 
diagnostic and prognostic utility of PCT in critically ill 
patients with suspected sepsis in ED and ICU, for whom 
sepsis was diagnosed clinically or on PCT concentra-
tions. Thus, our results are in accordance with those of 
Hur et al. [7], as we found similar PCT values in non-sur-
vivors (mean PCT at admission around 32 µg/L).
When considering our ROC curve analysis for death 
prediction, our results are similar to those of Zhao et al. 
[18] and to those of Wang et  al. [19], but with a higher 
cutoff. In our population, we observe similar perfor-
mances with the solely PCT, in comparison with that 
of Zhao when using MEDS score +PCT [18], or to that 
of Wang using PCT alone [19]. Wang et al. [19] found a 
28-day mortality cutoff at 4.3 µg/L, which is lower than 
ours, but they included both septic patients and SIRS 
patients without infection. MEDS score has been sug-
gested as a score system with high ability to predict the 
28-day outcome of ED patients with systemic inflamma-
tory response syndrome (SIRS), sepsis, or severe sepsis 
[20–22]. However, some studies indicated that MEDS 
score is not suitable for patients with severe sepsis or sep-
tic shock [23, 24].
We found that PCT is a moderate predictor of 30-day 
mortality but also for the prediction of death and/or 
admission in ICU in confirmed septic ED patients. Our 
results are in accordance with most of the previous stud-
ies [4, 7, 15–18]. However, some studies also failed to 
demonstrate any prognostic value of PCT [19]. In our 
septic population, the PCT value for predicting 30-day 
mortality is higher (32.5 vs 4.3 µg/L), with a better speci-
ficity (96 vs 84  %) than previously observed [19]. How-
ever, this strategy allows to target a small number of 
patients in our population (n = 19 deceased patients with 
Fig. 3 Outcomes (30‑day mortality and/or combination of ICU transfer) according to levels of PCT
Fig. 4 Outcome according to PCT and lactate thresholds. PCT and 
lactate thresholds were given by ROC analysis. Ratio indicates number 
of deceased patient at day 30 over number of patients in each 
category
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a PCT above 32.5  µg/L, corresponding to 51  % of the 
deceased patients but only 10 % of the whole study popu-
lation), and thus the interest of its use in routine might be 
limited.
Furthermore, when considering the ROC curve analy-
sis for the prediction of death and/or admission in ICU, 
prognostic performances were lower, and we did not find 
any significant difference in PCT values between patients 
admitted to ICU versus the others. This latest observa-
tion was somehow expected as many other factors (such 
as comorbidities including dementia, functional status, 
and bed availability…) are used in the decision to admit 
a patient in ICU. The weight of biological (as PCT) or 
physiological data is probably relatively low compared 
to other variables in the decision of ICU transfer, as 
reflected by our Fig. 3.
In our subgroup analysis, we did not observe any addi-
tional performance when combining lactate to PCT, for 
the prediction of 30-day mortality or for the prediction 
of death and/or admission in ICU. This is not in accord-
ance with results obtained by Freund et al. [3], who—in 
a larger sample of ED patients—considered a combined 
outcome (death and/or ICU admission and/or terminal 
patients with therapy limitations). However, our patients 
Table 2 Net reclassification table of patients according to PCT and lactate values
Death at 
30 days (n) Alive (n) Total (n) 
PCT>32.5 µg/L 








PCT and lactate below thresholdsa
15 





Total 26 77 103 
NB. This is the practical representation of both the relationship between false positive and false negative (gray zones), and the magnitude of the gain of predictability 
in quantitative terms (number of patients): here, the strategy PCT + lactates provokes a decrease in false negative (from 15 to 5) but a concomitant increase in 
false positives (from 3 to 32). The consequence is that sensitivity is improved (from 11/26 = 42.3 % to 21/26 = 80.8 %), but consequently specificity is dramatically 
decreased (from 74/77 = 96.1 % to 45/77 = 58.4 %)
Thus, the NRI calculation is: NRI = (80.8 + 58.4) − (42.3 + 96.1) = 0.8 %
a 32.5 µg/L for PCT, 2.2 mmol/L for lactate
Table 3 Univariate and multivariate analysis for independent prediction of death at 30 days
As data were partially collected for lactate and respiratory rate, these parameters could not be included in the analysis
Univariate analysis p Multivariate analysis p
OR [95 % CI] OR [95 % CI]
Age 1.04 [1.01–1.06] 0.0015 /
Heart rate 1.02 [1.00–1.03] 0.047 /
Personal history of:
 Cardiovascular diseases 2.5 [1.1–5.7] 0.024 3.1 [1.0–9.4] 0.0462
 Respiratory disease 2.4 [1.05–5.2] 0.036 /
 “Other” chronic diseases 0.4 [0.1–1.0] 0.052 /
Severe sepsis/septic shock 2.3 [1.1–4.8] 0.027 4.0 [1.3–12.3] 0.0130
PCT > 32.5 μg/L 21.7 [8.0–58.8] <0.0001 36.0 [10.0–128.4] <0.0001
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with both PCT > 32.5 µg/L and lactate >2.2 mmol/L pre-
sented the worst outcome, which suggests the potential 
complementary role of both biomarkers in identifying 
very high-risk patients. Unfortunately, using NRI and 
BLC methods, we failed in finding strong additional 
information in the association PCT + lactate. This might 
be because of the small subgroup number of patients and 
should be specifically investigated in a larger cohort.
Limitations
Some limitations merit consideration in this study. Firstly, 
this is a bicentric retrospective, non-blind study, includ-
ing a somehow limited number of patients. Secondly, 
we did not use severity score systems (MEDS, SOFA, 
etc.) to compare with, or in addition to PCT. Thirdly, 
the dynamic changes in biomarkers were not evaluated. 
Fourthly, we do not have data on previous antibiotherapy 
or antibiotics given in the ER or after. Thus, we do not 
have information on their adequacy. Fifthly, lactate was 
not measured systematically to all patients. Therefore, 
this variable could not be fully investigated and included 
in our multivariate analysis. Finally, two different meth-
ods were used to assay PCT. However, the two methods 
are known to be highly correlated [11, 12], and a minimal 
bias was observed in our population.
Conclusion
Elevated value of PCT at admission has moderate accu-
racy to identify poor outcome in ED septic patients. 
We suggest that the measurement of PCT in ED septic 
patients should not be routinely performed to assess 
prognostic information, before other evaluation of its 
added value in further studies.
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